Cytek Biosciences financials at a glance

+ Portfolio

The revenue of Cytek Biosciences is reported as 0.16404 billion Dollars in the fiscal year 2023. The earnings were 0.15 Dollars per share in 2023, which was 0 higher than 2022. And about -0.00181 billion Dollars are reported as free cash flow in the financials of Cytek Biosciences 2023. No dividends were paid to the shareholders of the Cytek Biosciences stock NasdaqGS:CTKB in the financial year 2023.

$164.04M

Revenue

$0.15

Earnings Per Share

56.81%

Gross Margin %

$0.00M

Free Cash Flow

Revenue

164.04

Earnings Per Share

0.15

Gross Margin %

56.81

Free Cash Flow

0.00

Financials

Year	Year	TTM	2023	2022	2021	2020
Rev.	Revenue	N/A	$164.04M	$164.04M	$127.95M	$0.00M
GM %	Gross Margin %	57.75%	56.81%	61.56%	61.86%	0.00%
OM	Operating Margin	-14.27%	-16.15%	-1.10%	7.34%	0.00%
EPS	Earnings Per Share	$-0.11	$0.15	$0.15	$0.09	$0.13
Div.	Dividends	N/A	$0.00	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	0.00%	0.00%	0.00%	0
Sha.	Shares	N/AM	130.71M	135.43M	134.08M	31.24M
OCF	Operating Cash Flow	N/A	$-1.81M	$0.00M	$0.00M	$0.00M
FCF	Free Cash Flow	N/A	$0.00M	$0.00M	$0.00M	$0.00M
FCFS	Free Cash Flow Per Share	$-0.06	$0.00	$-0.16	$0.00	$0.00

Cytek Biosciences financials at a glance

Financials

Discover